Tofacitinib in Scleritis: A Case Series

Richa Pyare, Parthopratim Dutta Majumder, Mauli Shah, Viswanathan Kaushik, Mamta Agarwal, Jyotirmay Biswas

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Purpose: To report the use of tofacitinib in ten patients with scleritis where the traditional immunomodulation was not successful or could not be used. Method: A retrospective chart review. Result: Tofacitinib was successful in the treatment of scleritis in patients either recalcitrant to or intolerant to conventional therapy in 9 out of 10 cases reported here. Two patients had developed reactivation of herpetic infection after 1 month of starting tofacitinib. The duration from diagnosis of scleritis to the institution of tofacitinib therapy varied from 1 month to 60 months. Duration of follow-up varies from 2 months to 11 months. Conclusion: Tofacitinib can be used as an important future option for managing recurrent and recalcitrant cases of scleritis.

Original languageEnglish (US)
JournalOcular Immunology and Inflammation
StateAccepted/In press - 2022
Externally publishedYes


  • JAK kinase inhibitor
  • necrotizing scleritis
  • nodular scleritis
  • scleritis
  • tofacitinib

ASJC Scopus subject areas

  • Immunology and Allergy
  • Ophthalmology


Dive into the research topics of 'Tofacitinib in Scleritis: A Case Series'. Together they form a unique fingerprint.

Cite this